Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 384; číslo 2; s. 129 - 139
Hlavní autoři: Bhatt, Deepak L, Szarek, Michael, Pitt, Bertram, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Inzucchi, Silvio E, Kosiborod, Mikhail N, Cherney, David Z.I, Dwyer, Jamie P, Scirica, Benjamin M, Bailey, Clifford J, Díaz, Rafael, Ray, Kausik K, Udell, Jacob A, Lopes, Renato D, Lapuerta, Pablo, Steg, P. Gabriel
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 14.01.2021
Témata:
Adverse events
Aged
Cardiovascular diseases
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Cerebral infarction
Confidence intervals
Congestive heart failure
Corporate sponsorship
Creatinine
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetic ketoacidosis
Diabetic Ketoacidosis - chemically induced
Diarrhea
Diarrhea - chemically induced
Double-Blind Method
Female
Glomerular filtration rate
Glucose
Glycosides - adverse effects
Glycosides - therapeutic use
Heart attacks
Heart failure
Hemoglobin
Hospitalization
Hospitalization - statistics & numerical data
Humans
Ketoacidosis
Kidney diseases
Male
Middle Aged
Mycoses - etiology
Myocardial infarction
Patients
Placebos
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - drug therapy
Risk factors
Sodium-glucose cotransporter
Sodium-Glucose Transporter 1 - antagonists & inhibitors
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Statistical analysis
Europe
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, mycotic infections, and diabetic ketoacidosis occurred with sotagliflozin.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2030186